Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
pediatric
Biotech
Longeveron’s phase 2b stem cell flop spurs cost cutting
The failure of the pediatric heart disease trial prompted the cash-strapped biotech to “review all options” for the business.
Nick Paul Taylor
Sep 17, 2026 4:40am
BrainChild masterminds $116M for pivotal pediatric cancer push
Sep 8, 2026 7:00am
Novo adds pediatric data to bulging bag of hemophilia A evidence
Feb 7, 2025 5:28am
FDA opens use of J&J's Impella heart pumps to pediatric patients
Dec 12, 2024 2:30pm
J&J posts adolescent myasthenia gravis data on $6B FcRn blocker
Oct 15, 2024 9:25am
FDA OKs Tandem’s automated insulin algorithm for toddlers
Nov 8, 2023 10:16am
